NCT03474263View on ClinicalTrials.gov

IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 1, 2019

Primary Completion Date

April 12, 2021

Study Completion Date

July 12, 2021

Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIOLOGICAL

Biologic: IC14 (monoclonal antibody against human CD14)

IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.

Trial Locations (1)

4006

Royal Brisbane & Women's Hospital, Herston

Sponsors
All Listed Sponsors
lead

Implicit Bioscience

INDUSTRY